Stockscreener 앱 받기
206.27
1.55%
-3.25
시장 영업 전:
206.53
0.26
+0.13%
Abbvie Inc 주식(ABBV)의 최신 뉴스
Looking At AbbVie's Recent Unusual Options Activity - Benzinga
Gubra’s AbbVie-partnered amylin looks competitive with Zealand’s in early trial - Endpoints News
Centric Wealth Management Acquires 8,508 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Legal Investigation: Cerevel's $22 Share Offering Scrutinized After $45 AbbVie Buyout - Stock Titan
Decoding AbbVie's Options Activity: What's the Big Picture? - Benzinga
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week - MSN
AbbVie: Margin Expansion Potential Can Support Elevated P/E (NYSE:ABBV) - Seeking Alpha
AbbVie to Host First-Quarter 2025 Earnings Conference Call - Investing News Network
Meta, Snowflake, PayPal And Health Care Stock On CNBC's 'Final Trades' - Benzinga
AbbVie Inc. (NYSE:ABBV) Shares Bought by Alliancebernstein L.P. - MarketBeat
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades. - The Motley Fool
Exclusive: SV Health debuts Parkinson’s biotech with backing from AbbVie and others - Endpoints News
AbbVie Inc. (NYSE:ABBV) Shares Sold by Level Four Advisory Services LLC - MarketBeat
AbbVie Inc. (ABBV): Among the Best Dividend Aristocrat Stocks with Over 3% Yield - MSN
RWA Wealth Partners LLC Has $55.27 Million Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Regulatory Condition Satisfied for License Agreement between AbbVie and Gubra - ACCESS Newswire
AbbVie Vs. Sanofi: Which Is The Better Investment Right Now (NYSE:ABBV) - Seeking Alpha
AbbVie (NYSE:ABBV) Stock Price Up 0.2%Should You Buy? - MarketBeat
AbbVie (ABBV) Rebounds After Consecutive Losses, Eyes Future Gro - GuruFocus.com
Regencell, GlucoTrack, TC Biopharm, AbbVie, Actinium: 5 Health Care Stocks That Lit Up Retail Discussions Last Week - MSN
AbbVie shares rose after seven consecutive sessions of losses (NYSE:ABBV) - Seeking Alpha
Corticosteroids Market May See a Big Move | Major Giants- AbbVie, Astellas Pharma, AstraZeneca - openPR
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
AbbVie (NYSE:ABBV) Showcases Oncology Innovations Amidst 6% Share Price Dip - Yahoo Finance
Non-Small Cell Lung Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeutics, AstraZeneca - Barchart
AbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025 - PR Newswire
2 Dividend Stocks Defying the Market Dip to Buy for a Lifetime of Passive Income - Yahoo Finance
AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market - MSN
AbbVie accuses oncology partner of stealing trade secrets - Crain's Chicago Business
AbbVie Inc (ABBV) Shares Gap Down to $202.37 on Mar 25 - GuruFocus
Smart Money Is Betting Big In ABBV OptionsAbbVie (NYSE:ABBV) - Benzinga
AbbVie sues Genmab, claiming trade secrets theft - pharmaphorum
AbbVie (ABBV) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Abbvie CEO Robert A. Michael's 2024 Total Compensation Was $18.5 MillionFiling -March 24, 2025 at 04:44 pm EDT - Marketscreener.com
AbbVie lawsuit alleges that partner Genmab “misappropriated” trade secrets - PharmaLive
Genmab stock falls amid AbbVie lawsuit By Investing.com - Investing.com South Africa
Genmab to Defend Against AbbVie’s Trade Secret Misappropriation Claims - TipRanks
Genmab stock falls amid AbbVie lawsuit - Investing.com
AbbVie Lawsuit Alleges That Partner Genmab "Misappropriated” Trade Secrets - BioSpace
Genmab faces trade secret claims by AbbVie - Investing.com India
Genmab Denies Trade Secret Misappropriation Claims by AbbVie -March 24, 2025 at 08:21 am EDT - Marketscreener.com
Allergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025 - AbbVie
Genmab dismisses Abbvie lawsuitaccused of exploiting trade secrets -March 24, 2025 at 03:30 am EDT - Marketscreener.com
Is AbbVie Inc. (ABBV) The Best Healthcare Dividend Stock to Invest in? - Insider Monkey
Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc. - GlobeNewswire
Genmab To Vigorously Defend Alleged Claims Of Trade Secret Misappropriation By Abbvie Inc. - Marketscreener.com
Is AbbVie Gaining or Losing Market Support?AbbVie (NYSE:ABBV) - Benzinga
Non-Small Cell Lung Cancer Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | AbbVie, Xcovery, Sanofi, Pfizer, Mirati Therapeutics, AstraZeneca, Daiichi Sankyo - Barchart
Open Angle Glaucoma Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Visiox Pharma, TearClear, VivaVision Biotech, Inc., Abbvie, Ocuphire Pharma, Qlaris Bio, Inc - The Globe and Mail
Botox Market Demand, Growth, Demand and Future Scope 2025-2032 | - openPR
AbbVie wins FDA nod for infusion treatment for advanced Parkinson’s disease - MSN
AbbVie Options Trading: A Deep Dive into Market Sentiment - Benzinga
Advancing Oncology: Innovations in Treatment and Detection - Value the Markets
Parkinson’s Disease Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis | AbbVie, Pfizer, Novartis, F. Roche, Kissei Pharma, AstraZeneca, Prevail Therapeutics, Amnea - Barchart
7.59%
자본화:
|
볼륨(24시간):